论文部分内容阅读
目的 :研究人白细胞介素 2 (hIL 2 )转基因小鼠淋巴瘤体内成瘤性。方法 :体外将hIL 2基因转入小鼠淋巴瘤p3 88细胞。用PCR、RT PCR、dotblot法检测hIL 2基因在细胞内的整合及表达 ,四甲基偶氮唑盐比色 (MTT)法检测转导细胞hIL 2分泌。体内试验将动物分为A9组、对照组和体内转染治疗组 3组。 17d后处死所有动物 ,观察肿瘤生长状况。结果 :hIL 2基因已成功地整合到小鼠p3 88细胞基因组内。p3 88/IL 2细胞分泌的hIL 2量为 3 7.4U·ml-1。A9组和体内转染治疗组动物肿瘤体积明显减小 ,与对照组肿瘤体积有显著性差异 (P <0 .0 5 )。结论 :hIL 2基因经体内或体外法转入p3 88/IL 2细胞后减弱了在小鼠体内的致瘤性
AIM: To investigate the in vivo tumorigenicity of human interleukin 2 (hIL 2) transgenic mouse lymphoma. Methods: The hIL 2 gene was transfected into mouse lymphoma p3 88 cells in vitro. The integration and expression of hIL 2 gene in the cells were detected by PCR, RT PCR and dotblot. The secretion of hIL 2 in the transduced cells was detected by MTT assay. In vivo experiments animals were divided into A9 group, control group and in vivo transfection treatment group 3 groups. After 17d, all animals were sacrificed to observe the tumor growth. Results: The hIL 2 gene has been successfully integrated into the mouse p3 88 cell genome. The amount of hIL2 secreted by p388 / IL2 cells was 3 7.4 U.ml-1. The tumor volume in A9 group and in vivo transfection group was significantly decreased, which was significantly different from that in control group (P <0.05). CONCLUSION: The hIL 2 gene attenuated tumorigenicity in mice after in vivo or in vitro transfection into p3 88 / IL 2 cells